Morphosys gets a major tafasitamab endorsement
Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.
A handful of huge gains stand out among mid and small-cap biotechs
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.
Sanofi goes all in with $2.5bn Synthorx buy
The French drugmaker bets big as it plays catch-up in the immuno-oncology space with a next-generation IL-2 buyout.
SITC – the morning after the night before
Nextcure’s Society for Immunotherapy of Cancer presentation gave investors little reason for cheer, but there's better news for Pieris, Celyad and Nektar.
SITC 2019 preview – Nextcure’s time to shine
The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.
Japanese drugmakers stand out at the nine-month mark
Daiichi Sankyo’s incredible stock market performance stands out amid the usual mixed bag of fallers and risers among biopharma’s mid- and small caps.
Nektar’s call for calm backfires
In blaming bempegaldesleukin’s falling efficacy on poor manufacturing Nektar has alarmed investors even more.
Go or no go? Abbvie, Roche and Kala await key decisions
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
Novel drug approvals head for a down year
With only 18 novel drugs approved by the FDA so far this year, the influential US regulator looks set to dim the green lights in 2019.
